Related Experiment Video
Updated: Oct 7, 2026

Intramuscular Transplantation of Human Pluripotent Stem Cell-derived Pancreatic Endocrine Cells in Mice
Published on: April 10, 2026
Pancreas transplantation for treatment of diabetes mellitus
D E Sutherland1, R W Gruessner, A C Gruessner
1Department of Surgery, University of Minnesota, Mayo Mail Code 280, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USA.
Abstract:
Pancreas transplantation is the only treatment for type I diabetes mellitus that can induce an insulin-independent normoglycemic state. Because of the need for immunosuppression, it has been most widely applied in uremic diabetic recipients of kidney transplant with a high success rate, particularly when done as a simultaneous (SPK) procedure (insulin independence > 80% at 1 year) with patient and kidney graft survival rates equivalent to or higher than in those who receive a kidney transplant alone. The results of solitary pancreas transplants (PAK in nephropathic diabetic recipients or PTA in nonuremic recipients) have also dramatically improved; 1-year graft survival rates are more than 80% and 70%, respectively, with the new immunosuppressants tacrolimus and mycophenolate mofetil. Multiple factors are important for successful application of pancreas transplantation, as summarized in this review.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Type I Diabetes I: Introduction

